Navigation Links
Anadys Pharmaceuticals Augments Management Team and Board of Directors
Date:1/6/2011

#160;

Dr. Appleman, who has been with Anadys since 2001 in positions of increasing responsibility, most recently as Senior Vice President, Research, played pivotal roles in the invention and characterization of the Company's drug development candidates ANA598 and ANA773.  Dr. Appleman will continue to be responsible for non-clinical aspects of both development programs.  Dr. Appleman was a faculty member at St. Jude Children's Research Hospital and subsequently held positions at Gensia, Inc. and Metabasis Therapeutics, Inc. prior to joining Anadys.  He received a Ph.D. in Biochemistry from Oklahoma State University and completed his postdoctoral training at Dartmouth Medical School.

Dr. Freddo joined Anadys in 2006 as Chief Medical Officer to build out the Company's clinical and regulatory functions and was named Senior Vice President of Drug Development in 2008.  Under his leadership both ANA598 and ANA773 entered clinical development and advanced to their current status.   Dr. Freddo joined Anadys from Pfizer, Inc. where he was most recently Vice President, Clinical Site Head and Development Site Head, La Jolla, and led the team responsible for the registration of Sutent®.  Prior to Pfizer, Dr. Freddo held a number of drug development positions at Wyeth-Ayerst.  Dr. Freddo serves as a member of the Board of Directors for InfuSystems Holdings, Inc.  Dr. Freddo received his M.D. and completed his fellowship training at the University of North Carolina and served on the faculty of the UCSD Medical Center prior to joining industry.

Dr. Papadopoulos assumes the role of Chairman of the Board from Steven H. Holtzman, who has resigned from the Board of Directors in association with his recent appointment as Executive Vice President, Corporate Development at Biogen Idec Inc.  Dr. Papadopoulos, who is a co-founder of Anadys and has been a member of the Board since 2000, has more than 25 years experience
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
2. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2009 Financial Results
3. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
4. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
5. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
6. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
7. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
8. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
9. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
10. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
11. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled a ... EST (11am PST), “Natural Language Processing: Converting Raw Data ... can turn raw, heterogeneous data into actionable knowledge to ... webinar will last approximately one hour. , Synopsis: Big ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of ... regulatory, business, and media events in the United States ... former associate Virginia Cox , JD, is returning to the ... Virginia Cox re-joins 3D after more than two years of ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Alba Therapeutics Corporation today,announced that its Investigational New ... endogenous insulin production capacity in new-onset,type 1 diabetes ... period,by the U.S. Food and Drug Administration (FDA). ... in 2008 while focusing the majority,of its development ...
... Sept. 5 Thermo Fisher,Scientific Inc. (NYSE: ... has,acquired the instrument sales business of Davis Inotek ... Instruments and excludes its,related calibration services. Davis Instruments ... control instruments, serving customers in a,wide range of ...
... A study in the August 2007,issue of ... GlycoMark,1,5-anhydroglucitol (1,5-AG) blood test to evaluate therapy ... hyperglycemia (elevated,after-meal glucose levels). Controlling after-meal glucose ... and reducing the burden of,cardiovascular complications, the ...
Cached Biology Technology:Alba Therapeutics Announces IND for Beta Cell Preservation in Type 1 Diabetes Using AT-1001 2Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek 2Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek 3Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek 4Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes 2
(Date:7/9/2014)... one of the amphibians with the highest distribution in ... of water where it comes into contact with the ... carried out by the Spaniard Germn Orizaola from the ... these frogs have developed a defensive response to the ... bodies if they co-exist with the crayfish. , Numerous ...
(Date:7/9/2014)... increase the survival rate of naturally aged animals? ... Pharmaceutical Sciences, Southwest University, China performed an animal ... low dose of levothyroxine for 3 consecutive months. ... obvious improvement in cognitive and an increased rat ... mechanism was demonstrated that levothyroxine treatment can increase ...
(Date:7/9/2014)... cancer patients with high levels of vitamin D in their ... shows. , Patients with the highest levels of vitamin ... with the lowest levels, the findings reveal. , The study ... D in bowel cancer patients after their diagnosis which ... from dietary sources with their long term survival prospects. ...
Breaking Biology News(10 mins):Frogs have developed rapid defences against the red swamp crayfish 2Frogs have developed rapid defences against the red swamp crayfish 3
... Mental Health (CAMH) is proud to announce a landmark ... Innovation (CFI) into research that will propel the understanding, ... to the next level of excellence. This ... Research Hospital Fund will allow CAMH to leverage our ...
... new study in the September issue of the Journal ... may have a role in the rising rate of diabetes, ... , DNA is the primary mechanism of inheritance; kids get ... scientists are just starting to understand additional kinds of inheritance ...
... invasion of unwanted species, according to a recent U.S. ... the reef and eliminate all the native coral, dramatically ... This study documents for the first time that a ... reef is unambiguously associated with man-made structures. ...
Cached Biology News:Large-scale investment catapults CAMH's mental illness and addiction research forward 2Shipwrecks on coral reefs harbor unwanted species 2
Recombinant Equine IL-6...
... Checker Kits provide two highly efficient methods ... time-consuming plasmid preparation. By using the large-scale ... need to do is to transfer partial ... the transformation plates into the solutions provided ...
... Butcher (1998). • The major histocompatibility complex ... the immunology area. There is great interest ... in their function as antigen-presenting molecules. Many ... prospect of tackling biochemical and genetic techniques ...
actin from rabbit muscle Cell Biology Cytoskeletal Probes Actin and Actin Probes...
Biology Products: